Blood · 2011 · 159 citations · 24 references
MedicineGeriatric MedicineOncologyGeriatricsGerontologyComprehensive Geriatric AssessmentGeriatric OncologyHodgkin Lymphoma CytologyHodgkin Lymphoma TherapyHodgkin Lymphoma TreatmentLymphoma StagingPrognostic Factors AnalysisRefractory Hodgkin LymphomaRelapsed Hodgkin LymphomaRelapsed Non-hodgkin Lymphoma
We investigated a recent (January 1999 to December 2009) cohort of 95 elderly Hodgkin lymphoma subjects. At diagnosis, median age was 67 years (range, 60-89 years), whereas 61% had significant comorbidity, 26% were unfit, 17% had a geriatric syndrome, and 13% had loss of activities of daily living. Overall response rate to therapy was 85%, whereas incidence of bleomycin lung toxicity was 32% (with associated mortality rate, 25%). With 66-month median follow-up, 2-year and 5-year overall survival were 73% and 58%, respectively (advanced-stage, 63% and 46%, respectively). Most International Prognostic Score factors were not prognostic on univariate analyses, whereas Cox multivariate regression identified 2 risk factors associated with inferior overall survival: (1) age more than 70 years (2.24; 95% CI, 1.16-4.33, P = .02) and (2) loss of activities of daily living (2.71; 95% CI, 1.07-6.84, P = .04). Furthermore, a novel survival model based on number of these risk factors (0, 1, or 2) showed differential 2-year OS of 83%, 70%, and 13%, respectively (P < .0001) and 5-year OS of 73%, 51%, and 0%, respectively (P < .0001).
24
A Prognostic Score for Advanced Hodgkin's Disease
Dirk Hasenclever, Volker Diehl, Jamés O. Armitage et al. · New England Journal of Medicine · 1998 · 1.7K citations · Full text
Veronika Ballová, Jens Ulrich Rüffer, Heinz Haverkamp et al. · Annals of Oncology · 2004 · 159 citations